Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BLRX with free AI briefings, catalyst countdowns, and dilution alerts.

BLRX · BioLineRx Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$13.1M Cash on Hand
14.5mo Cash Runway
Follow BLRX by email Get an email when BLRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BLRX, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
CYP-1020 Schizophrenia Phase 2/3 · NCT01363349 Terminated
Motixafortide (BL-8040) Multiple Myeloma Phase 3 · NCT03246529 Active not recruiting
Equine Thymocyte Immune Globulin Aplastic Anemia Phase 2 · NCT02462252 Completed
Hydroxychloroquine Hepatitis C Phase 1/2 · NCT01833845 Terminated
Linagliptin Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… Phase 1/2 · NCT03281369 Terminated
Methylprednisolone Aplastic Anemia Phase 2 · NCT02462252 Completed
Morphine Acute Pain Phase 1/2 · NCT00374881 Completed
PEGylated recombinant human hyaluronidase… Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… Phase 1/2 · NCT03281369 Terminated
Phenylephrine Acute Pain Phase 1/2 · NCT00374881 Completed
Sorbitol Acute Pain Phase 1/2 · NCT00374881 Completed
Tiragolumab Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… Phase 1/2 · NCT03281369 Terminated
BL-7010 Celiac Disease Phase 1/2 · NCT01990885 Completed
BL - 1020 Schizophrenia Phase 2 · NCT00567710 Completed
BL 1020 Schizophrenia Phase 2 · NCT00480571 Completed
BL-1020 Schizophrenia Phase 2 · NCT00722176 Completed
BL-1020 10-30 mg Schizophrenia Phase 2 · NCT00722176 Completed

Also used in these trials (approved or third-party drugs, not BLRX's own candidates): Risperidone, Paclitaxel, Leucovorin, Oxaliplatin, Pembrolizumab, Ramucirumab, Ribavirin, Atezolizumab, Cyclosporine, Cisplatin, Cobimetinib, Perphenazine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BLRX holds $13.1M in cash and short-term investments and burns about $2.7M/quarter from operations, an estimated runway of 14.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 22 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BLRX files for a raise →

👥 Who Owns BLRX

Insiders 0.4% Institutions (15 holders) 1.8% Public and other holders 97.8%
HolderTypeShares% of sharesAs of
Philip A Serlin
Chief Executive Officer
Insider 5,131,800 0.20% 2026-03-18
Aharon Schwartz
Director
Insider 3,705,000 0.14% 2026-03-18
Mali Zeevi
Chief Financial Officer
Insider 1,311,000 0.05% 2026-03-18
Armistice Capital, LLC Institution (13G, 5%+) 514,365 0.02% 2026-09-30

Share count 2,610,814,390 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BLRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BLRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.